NASDAQ:STAA - STAAR Surgical Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$29.25 -0.55 (-1.85 %)
(As of 06/17/2018 04:00 PM ET)
Previous Close$29.25
Today's Range$29.15 - $29.95
52-Week Range$9.50 - $31.75
Volume406,841 shs
Average Volume438,722 shs
Market Capitalization$1.22 billion
P/E Ratio2,925.00
Dividend YieldN/A
Beta1.37

About STAAR Surgical (NASDAQ:STAA)

STAAR Surgical logoSTAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and delivery systems to deliver the lenses into the eye. The company provides Visian implantable collamer lenses (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers minimally invasive intraocular lenses (IOLs), including foldable IOLs for use in minimally invasive cataract surgical procedures; aspheric IOLs that produce a clearer image than traditional spherical lenses; and nanoFLEX IOL, a single piece collamer aspheric optic, as well as preloaded injectors for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision centers, surgical centers, hospitals, government facilities, and distributors primarily under the STAAR, EVO Visian ICL, Evolution in Visual Freedom, Visian, Collamer, CentraFLOW, AquaPORT, nanoFLEX, nanoPOINT, and Afinity trademarks. The company sells products directly through its sales representatives in the United States, Japan, Spain, Germany, Canada, the United Kingdom, and Singapore, as well as through independent distributors in approximately 75 countries. STAAR Surgical Company was founded in 1982 and is headquartered in Monrovia, California.

Receive STAA News and Ratings via Email

Sign-up to receive the latest news and ratings for STAA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Ophthalmic goods
Sub-IndustryHealth Care Supplies
SectorMedical
SymbolNASDAQ:STAA
CUSIP85231230
Phone626-303-7902

Debt

Debt-to-Equity Ratio0.03
Current Ratio2.43
Quick Ratio1.90

Price-To-Earnings

Trailing P/E Ratio2,925.00
Forward P/E Ratio975.00
P/E GrowthN/A

Sales & Book Value

Annual Sales$90.61 million
Price / Sales13.44
Cash Flow$0.0914 per share
Price / Cash319.97
Book Value$1.04 per share
Price / Book28.13

Profitability

EPS (Most Recent Fiscal Year)$0.01
Net Income$-2,130,000.00
Net Margins0.66%
Return on Equity6.80%
Return on Assets4.04%

Miscellaneous

Employees353
Outstanding Shares41,620,000

STAAR Surgical (NASDAQ:STAA) Frequently Asked Questions

What is STAAR Surgical's stock symbol?

STAAR Surgical trades on the NASDAQ under the ticker symbol "STAA."

How were STAAR Surgical's earnings last quarter?

STAAR Surgical (NASDAQ:STAA) announced its quarterly earnings data on Wednesday, May, 2nd. The medical instruments supplier reported $0.04 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.04) by $0.08. The medical instruments supplier had revenue of $27.09 million for the quarter, compared to analyst estimates of $23 million. STAAR Surgical had a net margin of 0.66% and a return on equity of 6.80%. During the same period in the prior year, the business posted ($0.05) earnings per share. View STAAR Surgical's Earnings History.

When is STAAR Surgical's next earnings date?

STAAR Surgical is scheduled to release their next quarterly earnings announcement on Tuesday, July, 31st 2018. View Earnings Estimates for STAAR Surgical.

What price target have analysts set for STAA?

4 brokerages have issued 12-month price targets for STAAR Surgical's stock. Their predictions range from $21.00 to $23.00. On average, they anticipate STAAR Surgical's stock price to reach $21.6667 in the next year. View Analyst Ratings for STAAR Surgical.

What are Wall Street analysts saying about STAAR Surgical stock?

Here are some recent quotes from research analysts about STAAR Surgical stock:
  • 1. Canaccord Genuity analysts commented, "We hosted CEO Caren Mason for a day of investor meetings in the Mid- Atlantic last week, coming away from discussions with increased conviction in the merits of the STAA turnaround story. We think management has “primed the pump” (product pipeline) extraordinary well, and expect STAA to deliver revenue growth acceleration through 2020 at least. Timing of FDA re-inspection and Warning Letter “lift” is in the agency’s court, but we continue to get the sense that the firm has dedicated significant resources to satisfy FDA inspectors once they commence their unannounced visit. The US market clearly represents an enormous potential growth engine for STAA, so removal of the Warning Letter could be a bullish catalyst for the stock, in our view." (4/24/2018)
  • 2. According to Zacks Investment Research, "Staar Surgical Company has evolved to become a developer, manufacturer and global distributor of products used by ophthalmologists and other eye care professionals to improve or correct vision in patients suffering from refractive conditions, cataracts and glaucoma. " (4/12/2018)

Are investors shorting STAAR Surgical?

STAAR Surgical saw a decrease in short interest in the month of May. As of May 15th, there was short interest totalling 494,547 shares, a decrease of 49.1% from the April 30th total of 971,594 shares. Based on an average daily volume of 872,862 shares, the days-to-cover ratio is currently 0.6 days. Approximately 1.2% of the company's shares are short sold.

Who are some of STAAR Surgical's key competitors?

Who are STAAR Surgical's key executives?

STAAR Surgical's management team includes the folowing people:
  • Ms. Caren L. Mason, Chief Exec. Officer, Pres and Director (Age 64)
  • Dr. Keith Holliday, Chief Technology Officer (Age 55)
  • Mr. Samuel J. Gesten J.D., Chief Legal Officer & Corp. Sec. (Age 56)
  • Mr. Hans-Martin Blickensdoerfer, Sr. VP of Commercial Operations - Europe & China (Age 53)
  • Ms. Deborah Andrews, Chief Financial Officer (Age 61)

Has STAAR Surgical been receiving favorable news coverage?

Press coverage about STAA stock has trended somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. STAAR Surgical earned a news impact score of 0.20 on Accern's scale. They also gave media headlines about the medical instruments supplier an impact score of 45.05 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

Who are STAAR Surgical's major shareholders?

STAAR Surgical's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Palo Alto Investors LP (8.45%), BlackRock Inc. (6.53%), Baillie Gifford & Co. (2.58%), Cortina Asset Management LLC (0.95%), Millennium Management LLC (0.79%) and Principal Financial Group Inc. (0.50%). Company insiders that own STAAR Surgical stock include Broadwood Partners Lp, Caren L Mason, Deborah J Andrews, Hans-Martin Blickensdoerfer, Keith Holliday and Samuel J Gesten. View Institutional Ownership Trends for STAAR Surgical.

Which institutional investors are selling STAAR Surgical stock?

STAA stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Cortina Asset Management LLC, Lincoln National Corp, A.R.T. Advisors LLC, Principal Financial Group Inc., Principal Financial Group Inc., Barclays PLC and Public Employees Retirement Association of Colorado. Company insiders that have sold STAAR Surgical company stock in the last year include Caren L Mason, Deborah J Andrews, Keith Holliday and Samuel J Gesten. View Insider Buying and Selling for STAAR Surgical.

Which institutional investors are buying STAAR Surgical stock?

STAA stock was bought by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., King Luther Capital Management Corp, Next Century Growth Investors LLC, BlackRock Inc., Millrace Asset Group Inc., Palo Alto Investors LP, Element Capital Management LLC and GSA Capital Partners LLP. View Insider Buying and Selling for STAAR Surgical.

How do I buy shares of STAAR Surgical?

Shares of STAA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is STAAR Surgical's stock price today?

One share of STAA stock can currently be purchased for approximately $29.25.

How big of a company is STAAR Surgical?

STAAR Surgical has a market capitalization of $1.22 billion and generates $90.61 million in revenue each year. The medical instruments supplier earns $-2,130,000.00 in net income (profit) each year or $0.01 on an earnings per share basis. STAAR Surgical employs 353 workers across the globe.

How can I contact STAAR Surgical?

STAAR Surgical's mailing address is 1911 WALKER AVENUE, MONROVIA CA, 91016. The medical instruments supplier can be reached via phone at 626-303-7902 or via email at [email protected]


MarketBeat Community Rating for STAAR Surgical (STAA)

Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  134 (Vote Outperform)
Underperform Votes:  220 (Vote Underperform)
Total Votes:  354
MarketBeat's community ratings are surveys of what our community members think about STAAR Surgical and other stocks. Vote "Outperform" if you believe STAA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe STAA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.